Results 171 to 180 of about 51,902 (295)

STAT-independent functions of Janus kinases 1 and 2 are obligatory for the postnatal development of mammary epithelial ducts. [PDF]

Cell Rep
Dennaoui R, Wicker MN, Moen C, Schlederer M, Vistisen K, Triplett AA, Rülicke T, Rui H, Kenner L, Casanova E, Wagner KU.   +10 more
europepmc   +1 more source

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity. [PDF]

Mol Biol Rep
Hanspal MA, Presland J, Shkura K, Veiga MK, Gillotin S.   +4 more
europepmc   +1 more source

Effect of 6,7-dimethoxy-2,2-dimethyl-2H-chromene (agerarin) on the recovery of filaggrin expression through targeting of Janus kinases in the inflammatory skin. [PDF]

J Food Drug Anal, 2020
Ahn SS, Lee YH, Yeo H, Lee Y, Min DS, Lim Y, Shin SY.   +6 more
europepmc   +1 more source

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor‐Modulating Agent in the Treatment of Atopic Dermatitis

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL‐4 and IL‐13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that ...
Gaku Tsuji, Yoko Fuyuno, Koji Kawamura, Ayako Yumine, Masaki Takemura, Yasutaka Mitamura, Kazuhiko Yamamura, Takeshi Nakahara   +7 more
wiley   +1 more source

Epigenomic landscapes define differential Janus kinases inhibitor sensitivity in IFN-γ-primed human macrophages. [PDF]

iScience
Kwon G, Park Y, Kang K, Park-Min KH, Kang K.   +4 more
europepmc   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Systematic review of Janus kinases inhibitors for rheumatoid arthritis: methodology, reporting, and quality of evidence evaluation. [PDF]

Front Pharmacol
Shen X, Liu X, Guo X, Hou X, Huang H, Feng Z.   +5 more
europepmc   +1 more source

Anisodamine Maintains the Stability of Intervertebral Disc Tissue by Inhibiting the Senescence of Nucleus Pulposus Cells and Degradation of Extracellular Matrix via Interleukin-6/Janus Kinases/Signal Transducer and Activator of Transcription 3 Pathway. [PDF]

Front Pharmacol, 2020
Tang N, Dong Y, Chen C, Zhao H.
europepmc   +1 more source